Antengene

95 articles about Antengene

• Antengene Presents Four Preclinical Posters at AACR 2024

  4/6/2024

  Antengene Corporation Limited announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting, taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States.

• Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline

  3/22/2024

  Antengene Corporation Limited announced its full year results for the period ended December 31, 2023, and provided an update on the impressive progress of its clinical development pipeline over the last several months.

• Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia

  3/20/2024

  Antengene Corporation Limited today announced that  it has initiated the dose expansion portion of the Phase II CLINCH study of ATG-022 (Claudin 18.2 antibody-drug conjugate[ADC]) in China and Australia.

• Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List

  12/14/2023

  Antengene Corporation Limited announced that XPOVIO® has been added to the National Reimbursement Drug List for the treatment of adult patients with relapsed or refractory multiple myeloma whose disease is refractory to at least one proteasome inhibitors, one immunomodulatory agent, and an anti-CD38 monoclonal antibody.

• Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States

  12/11/2023

  Antengene Corporation Limited announced that the first patient has been dosed in the Phase I PERFORM trial of ATG-031 for the treatment of patients with advanced solid tumors or B-cell non-Hodgkin's lymphoma, at The University of Texas MD Anderson Cancer Center, the lead center of the study that also includes three other clinical trial centers across the U.S.

• Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

  12/6/2023

  Antengene Corporation Limited announced that the Pharmaceutical Administration Bureau of Macau has approved a New Drug Application for XPOVIO®.

• Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs

  11/8/2023

  Antengene Corporation Limited announced that it will host its 2023 R&D Day on November 17, 2023, to update the medical and investor communities on the company's progress with its R&D programs.

• Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting

  11/1/2023

  Antengene Corporation Limited announced that it has presented results from five programs by poster presentation, including two clinical programs on the anti-CD24 monoclonal antibody ATG-031 and the PD-L1/4-1BB bispecific antibody ATG-101.

• Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting

  9/28/2023

  Antengene Corporation Limited announced that it will present five programs at the 2023 Society of Immunology in Cancer Annual Meeting to be held in San Diego from November 1-5, 2023.

• Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

  9/21/2023

  Antengene Corporation Limited today announced that a Phase I study of the best-in-class anti-CD24 antibody, ATG-031, has been approved by the Institutional Review Board (IRB) of The University of Texas MD Anderson Cancer Center in Houston, Texas, the United States. 

• Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States

  7/18/2023

  Antengene Corporation Limited announced that the first patient has been dosed in the United States in the combination portion of the Phase I ERASER trial to evaluate ATG-017 plus nivolumab.

• Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma

  7/17/2023

  Antengene Corporation Limited announced that the Department of Health, the Government of the HKSAR has approved a NDA for XPOVIO®.

• Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma

  6/1/2023

  Antengene Corporation Limited announced that XPOVIO® in combination with bortezomib and dexamethasone is now listed on the PBS for the treatment of adult patients with R/R MM who have received at least one prior therapy.

• Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023

  5/26/2023

  Antengene Corporation Limited announced that the latest results from the Phase I/II TORCH-2 study will be presented as a poster at the 2023 American Society for Clinical Oncology Annual Meeting taking place from June 2nd to 6th, 2023 at the McCormick Place Convention Center in Chicago, IL.

• Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

  5/23/2023

  Antengene Corporation Limited announced that ATG-022, a Claudin 18.2 antibody drug conjugate in-house discovered and developed by Antengene, has been granted two Orphan Drug Designations consecutively by the U.S. Food and Drug Administration for the treatment of gastric cancer and pancreatic cancer.

• Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO

  4/27/2023

  Antengene Corporation Limited announced that the results of the Phase I/II TORCH-2 study will be presented as a poster discussion during the American Society for Clinical Oncology Annual Meeting, taking place from June 2nd to 6th at the McCormick Place Convention Center in Chicago, IL.

• Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting

  4/17/2023

  Antengene Corporation Limited today announced the presentation of five posters at the American Association for Cancer Research Annual Meeting 2023 Meetings (AACR 2023), taking place from April 14th to 19th at the Orange County Convention Center in Orlando, Florida, the United States.

• Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation

  3/28/2023

  Antengene Corporation Limited today announced its full-year 2022 financial results and provided updates on key events and achievements since the start of 2022.

• Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting

  3/20/2023

  Antengene Corporation Limited announced the publication of abstracts for five posters that will be presented during the upcoming 2023 American Association for Cancer Research Annual Meeting, taking place from April 14th to 19th at the Orange County Convention Center in Orlando, Florida, the United States.

• Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Antengene Corporation Limited announced that Antengene will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th, 2023 at 9:30 a.m. PST in San Francisco, California.